Both the Lilly and Novo Nordisk pills resulted in less weight loss than the average achieved with Lillys injectable Zepbound, which results in a 21% average weight loss, or Novo Nordisks injectable Wegovy, which averages about 15%
Key Findings (20-year risks in early-onset AF vs matched controls): Stroke: 6.9% | 2x higher risk Heart Failure: 6.5% | 45x higher risk Death: 7.1% | 1.4x higher risk Take-home message: Even in the absence of traditional comorbidities, early-onset AF is a marker of future cardiovascular complicationsespecially cardiomyopathy and HF
Why GLP-1 medications are so expensive Brand-name GLP-1 drugs like Ozempic, Wegovy, Mounjaro, and Zepbound carry high list prices, commonly exceeding a thousand dollars a month at retail
Every plan is thoughtfully designed around your goals, your symptoms, and how you want to feel, with clinical insight guiding each recommendation